HYMPAVZI®
(marstacimab)
PFIZER
HK Reg. No. HK-68832 (28 Aug, 2025)
Composition:3
• Hympavzi 150 mg solution for injection in pre-filled pen: Each pre-filled pen contains 150 mg marstacimab in 1 mL of solution
Indication:3
Hympavzi is indicated for routine prophylaxis of bleeding episodes in patients 12 years of age and older,
weighing at least 35 kg, with
• Severe hemophilia A (congenital factor VIII deficiency, FVIII < 1%) without factor VIII inhibitors, or
• Severe hemophilia B (congenital factor IX deficiency, FIX < 1%) without factor IX inhibitors
References
3. EMA. Hympavzi Summary of Product Characteristics. Available from: https://www.ema.europa.eu/en/documents/product-information/hympavzi-epar-product-information_en.pdf. [Accessed 18 September 2025].
